Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Bio-Path Holdings Reports First Quarter 2018 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis

Stock Monitor: Bio-Path Holdings Post Earnings Reporting

ARDM : 1.67 (+0.60%)
BPTH : 1.60 (+3.23%)
Bio-Path Leukemia Combo Study Shows Positive Early Data

Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

LGND : 198.40 (-0.63%)
ENTA : 119.60 (+0.51%)
REGN : 331.97 (+0.89%)
BPTH : 1.60 (+3.23%)
Bio-Path Holdings Reports Full Year 2017 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Bio-Path Holdings, Inc. (NASDAQ: ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018 at 8:30 AM Eastern Time.

BPTH : 1.60 (+3.23%)
Bio-Path Holdings Announces Publication in The Lancet Haematology

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting

Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings to Present at the 30th Annual ROTH Conference

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings Announces 1-for-10 Reverse Stock Split

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings to Present at the BIO CEO & Investor Conference

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings Appoints Paul Aubert to its Board of Directors

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Pre-Market Technical Scan on Drug Delivery Equities -- Bio-Path, Alkermes, PetMed Express, and Valeant Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on BPTH, ALKS, PETS, and VRX which can be accessed for free by signing up to www.wallstequities.com/registration....

PETS : 45.77 (+1.91%)
BPTH : 1.60 (+3.23%)
ALKS : 44.13 (+1.10%)
VRX : 24.27 (-1.82%)
Bio-Path Holdings Reports Third Quarter 2017 Financial Results

Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering

Bio-Path Holdings, Inc., (NASDAQ:BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer...

BPTH : 1.60 (+3.23%)
Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.60 (+3.23%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -2.19 , FTNT -0.81 , CAKE -2.16 , PLT -0.20 , AEO -0.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed Friday steady to fractionally mixed, as July was down 1.11% on the week. The USDA reported a private export sale of 131,300 MT of corn to Mexico this morning. The sale was broke down to 30,000 MT for delivery in 2017/18, with the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar